Clinical Trials in Ontario

Below is a list of planned or ongoing clinical trials in Ontario provided for information purposes. Please read the information regarding inclusion and exclusion criteria closely before contacting investigators for enrolment. Only contact if you meet their criteria. Other trials can be found at ClinicalTrials.gov and the Stanford University Coronavirus Antiviral Research Database

CONCOR-1

CONCOR-1

Study Design & Outcomes

Study Type

RCT

Study Arms

1) COVID-19 convalescent plasma + standard care

2) Standard care


2:1 Enrolment (Treatment:Control)

Primary Outcome

In-hospital mortality

Inclusion & Exclusion Criteria

Inclusion

  1. Age >/= 16 years 

  2. Admitted to the hospital with confirmed COVID-19 illness

  3. Receiving supplemental oxygen for COVID-19 illness

  4. 500mL ABO-compatible convalescent plasma available

Exclusion

Please contact investigators for details

RAPID COVID COAG

RAPID COVID COAG

Study Design & Outcomes

Study Type

Open-Label RCT

Study Arms

1) LMWH DVT prophylaxis

2) LMWH therapeutic

Primary Outcome

composite of mortality and respiratory failure

Inclusion & Exclusion Criteria

Inclusion

  • D-dimer 2X upper limit of normal

  • Hospitalized (Not in ICU)

  • Receiving Supplemental Oxygen

Exclusion

Please contact investigators for details

Michelle Sholzberg

COVID-19 PEP

Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP)

Study Design & Outcomes

Study Type

RCT

Study Arms

Hydroxychloroquine vs placebo

Primary Outcome

preventing COIVD-19 and/or decreasing severity

Inclusion & Exclusion Criteria

Inclusion

Adults >18 years:

  • with symptoms beginning in the past 4 days   and a confirmed diagnosis of COVID-19 via testing, and are self-isolating at   home (not in hospital); OR
     - healthcare worker with symptoms for the last 4 days or less and had   contact with a patient with confirmed COVID-19 in the past 14 days; OR
  • who are a household member without symptoms exposed   in the last 4 days to a person with known COVID-19; OR
  • who are a healthcare without symptoms with a moderate to high risk contact in the last 4 days to a patient with known COVID-19

Exclusion

Please contact investigators for details

Todd Lee

enrollment via IPAC and Toronto Public Health contact tracing

CATCO

Canadian Treatments for COVID-19

Study Design & Outcomes

Study Type

Open-Label RCT

Study Arms

1) Remdesivir

2) Hydroxychloroquine

3) Kaletra [lopinavir/ritonavir]

4) Supportive care

5) Kaletra + IFN-B1a + Optimized Supportive care*   (*not in Canada)

Primary Outcome

In-Hospital Mortality

Inclusion & Exclusion Criteria

Inclusion

  • SARCS-CoV2 infection

Exclusion

Please contact investigators for details

Srinivas Murthy

© 2020 COVID19-ASK. All Rights Reserved. Terms of Use.

The contents on COVID19Ask.com, such as text, graphics, images, and other materials created by the contributors to COVID19Ask.com or obtained from third parties, and other materials contained on COVID19Ask.com (collectively, the “Content”) are for informational purposes only.

The Content provided on COVID19Ask.com is not designed or intended to constitute medical advice, or to be used for diagnosis. Always seek the advice of your personal physician or other qualified health provider to determine the appropriateness of any Content for your specific situation and before making any decision regarding your treatment or medication. Never disregard professional medical advice or delay seeking it based on a self-assessment with reference to the Content.

Reliance on any information provided by  the contributors to COVID19Ask.com, COVID19Ask.com employees, others appearing on COVID19Ask.com at the invitation of the contributors to COVID19Ask.com, or other visitors to COVID19Ask.com is solely at your own risk.

If you think you may have a medical emergency, call your doctor or dial 911 immediately. The contributors to COVID19Ask.com do not recommend or endorse any specific tests, physicians, products, procedures, opinion, or other information that may be mentioned on COVID19Ask.com.